Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer

Francesca V. Negri, Pellegrino Crafa, Giuseppe Pedrazzi, Cecilia Bozzetti, Costanza Lagrasta, Giorgio Gardini, Ione Tamagnini, Alessandra Bisagni, Cinzia Azzoni, Lorena Bottarelli, Gallia Graiani, Ida Romano, Rosa Porzio, Gian P. Bacchini, Carlo Paties, Gianluca Tomasello, Giovanni Marchetti, Silvia Fanello, Carmine Pinto, Roberto SalaAndrea Ardizzoni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.

Original languageEnglish
Pages (from-to)3167-3174
Number of pages8
JournalFuture Oncology
Volume11
Issue number23
DOIs
Publication statusPublished - 2015

Fingerprint

Colorectal Neoplasms
Immunohistochemistry
Drug Therapy
Disease-Free Survival
Randomized Controlled Trials
Bevacizumab

Keywords

  • bevacizumab
  • colorectal cancer
  • DLL4
  • Notch activation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Negri, F. V., Crafa, P., Pedrazzi, G., Bozzetti, C., Lagrasta, C., Gardini, G., ... Ardizzoni, A. (2015). Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. Future Oncology, 11(23), 3167-3174. https://doi.org/10.2217/fon.15.218

Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. / Negri, Francesca V.; Crafa, Pellegrino; Pedrazzi, Giuseppe; Bozzetti, Cecilia; Lagrasta, Costanza; Gardini, Giorgio; Tamagnini, Ione; Bisagni, Alessandra; Azzoni, Cinzia; Bottarelli, Lorena; Graiani, Gallia; Romano, Ida; Porzio, Rosa; Bacchini, Gian P.; Paties, Carlo; Tomasello, Gianluca; Marchetti, Giovanni; Fanello, Silvia; Pinto, Carmine; Sala, Roberto; Ardizzoni, Andrea.

In: Future Oncology, Vol. 11, No. 23, 2015, p. 3167-3174.

Research output: Contribution to journalArticle

Negri, FV, Crafa, P, Pedrazzi, G, Bozzetti, C, Lagrasta, C, Gardini, G, Tamagnini, I, Bisagni, A, Azzoni, C, Bottarelli, L, Graiani, G, Romano, I, Porzio, R, Bacchini, GP, Paties, C, Tomasello, G, Marchetti, G, Fanello, S, Pinto, C, Sala, R & Ardizzoni, A 2015, 'Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer', Future Oncology, vol. 11, no. 23, pp. 3167-3174. https://doi.org/10.2217/fon.15.218
Negri FV, Crafa P, Pedrazzi G, Bozzetti C, Lagrasta C, Gardini G et al. Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. Future Oncology. 2015;11(23):3167-3174. https://doi.org/10.2217/fon.15.218
Negri, Francesca V. ; Crafa, Pellegrino ; Pedrazzi, Giuseppe ; Bozzetti, Cecilia ; Lagrasta, Costanza ; Gardini, Giorgio ; Tamagnini, Ione ; Bisagni, Alessandra ; Azzoni, Cinzia ; Bottarelli, Lorena ; Graiani, Gallia ; Romano, Ida ; Porzio, Rosa ; Bacchini, Gian P. ; Paties, Carlo ; Tomasello, Gianluca ; Marchetti, Giovanni ; Fanello, Silvia ; Pinto, Carmine ; Sala, Roberto ; Ardizzoni, Andrea. / Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. In: Future Oncology. 2015 ; Vol. 11, No. 23. pp. 3167-3174.
@article{1d840856d965469a80e6bde9773228c7,
title = "Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer",
abstract = "Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62{\%} in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.",
keywords = "bevacizumab, colorectal cancer, DLL4, Notch activation",
author = "Negri, {Francesca V.} and Pellegrino Crafa and Giuseppe Pedrazzi and Cecilia Bozzetti and Costanza Lagrasta and Giorgio Gardini and Ione Tamagnini and Alessandra Bisagni and Cinzia Azzoni and Lorena Bottarelli and Gallia Graiani and Ida Romano and Rosa Porzio and Bacchini, {Gian P.} and Carlo Paties and Gianluca Tomasello and Giovanni Marchetti and Silvia Fanello and Carmine Pinto and Roberto Sala and Andrea Ardizzoni",
year = "2015",
doi = "10.2217/fon.15.218",
language = "English",
volume = "11",
pages = "3167--3174",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "23",

}

TY - JOUR

T1 - Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer

AU - Negri, Francesca V.

AU - Crafa, Pellegrino

AU - Pedrazzi, Giuseppe

AU - Bozzetti, Cecilia

AU - Lagrasta, Costanza

AU - Gardini, Giorgio

AU - Tamagnini, Ione

AU - Bisagni, Alessandra

AU - Azzoni, Cinzia

AU - Bottarelli, Lorena

AU - Graiani, Gallia

AU - Romano, Ida

AU - Porzio, Rosa

AU - Bacchini, Gian P.

AU - Paties, Carlo

AU - Tomasello, Gianluca

AU - Marchetti, Giovanni

AU - Fanello, Silvia

AU - Pinto, Carmine

AU - Sala, Roberto

AU - Ardizzoni, Andrea

PY - 2015

Y1 - 2015

N2 - Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.

AB - Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.

KW - bevacizumab

KW - colorectal cancer

KW - DLL4

KW - Notch activation

UR - http://www.scopus.com/inward/record.url?scp=84971667778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971667778&partnerID=8YFLogxK

U2 - 10.2217/fon.15.218

DO - 10.2217/fon.15.218

M3 - Article

C2 - 26552022

AN - SCOPUS:84971667778

VL - 11

SP - 3167

EP - 3174

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 23

ER -